Alumis Shares Phase 3 Psoriasis Details, Targets 2H NDA Filing at Oppenheimer Healthcare Conference [Yahoo! Finance]
Alumis Inc. (ALMS)
Company Research
Source: Yahoo! Finance
16, with deeper responses by week 24 including about PASI 90 ~65% and PASI 100 just over 40% , and clinical separation from placebo emerging as early as week 4. The Phase 3 safety profile was consistent with Phase 2—most common adverse events were headaches, upper respiratory infections, nasopharyngitis and acne—Alumis reported no malignancy signal and no lab chemistry changes suggesting routine monitoring would be required. Alumis plans an NDA in the second half of the year after receiving 48-week data by mid-year, expects a likely commercial partnership decision by year-end, and is targeting a pivotal lupus (SLE) readout in the third quarter with potential additional Phase 3 discussions depending on the dataset. Interested in Alumis Inc.? Here are five stocks we like better. 3 Biopharmaceutical Stocks Bucking the Sell-Off Executives from Alumis (NASDAQ:ALMS) outlined upcoming regulatory milestones and provided additional context around recently announced Phase 3 psoriasis
Show less
Read more
Impact Snapshot
Event Time:
ALMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALMS alerts
High impacting Alumis Inc. news events
Weekly update
A roundup of the hottest topics
ALMS
News
- Alumis to Present at the Leerink Partners Global Healthcare ConferenceGlobeNewswire
- Alumis (ALMS) is now covered by Stifel Nicolaus. They set a "buy" rating and a $44.00 price target on the stock.MarketBeat
- Alumis to Participate in Upcoming February Investor ConferencesGlobeNewswire
- Alumis (NASDAQ:ALMS) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.MarketBeat
- Alumis (NASDAQ:ALMS) was given a new $37.00 price target on by analysts at Loop Capital.MarketBeat
ALMS
Sec Filings
- 2/11/26 - Form 5
- 1/30/26 - Form S-8
- 1/28/26 - Form 4
- ALMS's page on the SEC website